Inhaled immunosuppressants after lung transplantation –real potential to enhance patient outcomes DOI Creative Commons

Gregory I. Snell,

Samantha Ennis,

Bronwyn Levvey

et al.

Expert Review of Respiratory Medicine, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 3

Published: Nov. 27, 2024

Language: Английский

Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review DOI Creative Commons

Mahmoud H. Abu Elella,

Arwa Omar Al Khatib, Hisham Al-Obaidi

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(5), P. 680 - 680

Published: May 17, 2024

Lung diseases have received great attention in the past years because they contribute approximately one-third of total global mortality. Pulmonary drug delivery is regarded as one most appealing routes to treat lung diseases. It addresses numerous drawbacks linked traditional dosage forms. presents notable features, such as, for example, a non-invasive route, localized delivery, low enzymatic activity, degradation, higher patient compliance, and avoiding first-pass metabolism. Therefore, pulmonary route commonly explored delivering drugs both locally systemically. Inhalable nanocarrier powders, especially, lipid nanoparticle formulations, including solid-lipid nanostructured-lipid nanocarriers, are attracting considerable interest addressing respiratory thanks their significant advantages, deep deposition, biocompatibility, biodegradability, mucoadhesion, controlled released. Spray drying scalable, fast, commercially viable technique produce nanolipid powders. This review highlights ideal criteria inhalable spray-dried SLN NLC powders administration route. Additionally, promising inhalation devices, known dry powder inhalers (DPIs) powder-based medications, applications treating chronic conditions, considered.

Language: Английский

Citations

7
Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS) DOI Creative Commons
Clarence T. Dhege, Pradeep Kumar, Yahya E. Choonara

et al.

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 657, P. 124182 - 124182

Published: April 30, 2024

Language: Английский

Citations

5
The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy DOI Creative Commons

Allana Carvalho Silva,

Mirsiane Pascoal Costa,

Thiago Medeiros Zacaron

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(8), P. 969 - 969

Published: July 23, 2024

Lung cancer is the leading cause of cancer-related mortality worldwide, largely due to limited efficacy anticancer drugs, which primarily attributed insufficient doses reaching lungs. Additionally, patients undergoing treatment experience severe systemic adverse effects distribution drugs non-targeted sites. In light these challenges, there has been a growing interest in pulmonary administration for lung cancer. This route allows be delivered directly lungs, resulting high local concentrations that can enhance antitumor while mitigating toxic effects. However, poses challenge overcoming mechanical, chemical, and immunological defenses respiratory tract prevent inhaled drug from properly penetrating To overcome drawbacks, use nanoparticles inhaler formulations may promising strategy. Nanoparticles assist minimizing clearance, increasing penetration into epithelium, enhancing cellular uptake. They also facilitate increased stability, promote controlled release, delivery target sites, such as tumor environment. Among them, chitosan-based demonstrate advantages over other polymeric nanocarriers their unique biological properties, including activity mucoadhesive capacity. These properties have potential when administered via route. view above, this paper provides an overview research conducted on drug-loaded incorporated devices Furthermore, article addresses emerging technologies, siRNA (small interfering RNA), context therapy. Particularly, recent studies employing are described.

Language: Английский

Citations

5
Konjac glucomannan exerts regulatory effects on macrophages and its applications in biomedical engineering DOI

Xi Pan,

Qida Zong,

Chun Liu

et al.

Carbohydrate Polymers, Journal Year: 2024, Volume and Issue: 345, P. 122571 - 122571

Published: Aug. 5, 2024

Language: Английский

Citations

5
Current advances in the therapeutic potential of nanomedicines for pulmonary disorders DOI
Mayank Sharma, Rahul K. Shah,

Apeksha Saraf

et al.

Emergent Materials, Journal Year: 2024, Volume and Issue: unknown

Published: April 24, 2024

Language: Английский

Citations

4
Enhancing Lung Recovery: Inhaled Poly(lactic-co-glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology DOI Creative Commons
H Zhang, Wen‐Shuo Kuo,

Pei-Yun Tu

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 18, 2025

Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), a rapidly progressing failure condition, results in high mortality rate, especially severe cases. Numerous trials have investigated various pharmacotherapy approaches, but their effectiveness remains uncertain. Here, we present an inhaled nanoformulation of fingolimod (FTY720)-nobiletin (NOB)- poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) with good biocompatibility and sustained-release pharmacological effect. The formulation decreases the toxicity FTY720 increases bioavailability NOB since use PLGA to encapsulate at same time. In vitro, comparison treatment pure drug, demonstrated that FTY720-NOB-PLGA NPs can reduce interleukin-6 (IL-6) reactive oxygen species (ROS) release by macrophages after lipopolysaccharide (LPS) stimulation more efficiently. vivo, used inhalation tower system allowed exposure unanesthetized mice aerosolized under controlled conditions. We attenuate LPS suppressing cytokine release, such as IL-6 tumor necrosis factor-α (TNF-α). trigger pathway ALI, including nuclear factor κ-light-chain-enhancer activated B cells (NF-κB) p38 mitogen-activated protein kinase, was also efficiently inhibited. Furthermore, provided safety profile, without detrimental effects on biochemical markers function. feasibility administering noninvasively continuous monitoring developed show excellent promise for acute therapy future.

Language: Английский

Citations

0
Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments? DOI Creative Commons
Meekha George, Rabah Boukherroub,

Amitav Sanyal

et al.

Materials Today Bio, Journal Year: 2025, Volume and Issue: 31, P. 101616 - 101616

Published: Feb. 26, 2025

Language: Английский

Citations

0
Natural deep eutectic solvents (NADES) in drug delivery systems: Characteristics, applications, and future perspectives DOI
Hui Li,

Kaining Yang,

Yumin Yang

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125509 - 125509

Published: March 1, 2025

Language: Английский

Citations

0
Formulation Approaches for Proliposomes in Pulmonary Drug Delivery DOI

Abdelbary Elhissi,

Dana Elkhalifa, Iftikhar Khan

et al.

Synthesis lectures on biomedical engineering, Journal Year: 2025, Volume and Issue: unknown, P. 63 - 112

Published: Jan. 1, 2025

Language: Английский

Citations

0
Quality by Design in Pulmonary Drug Delivery: A Review on Dry Powder Inhaler Development, Nanotherapy Approaches, and Regulatory Considerations DOI

Ashish Dilip Sutar,

Rahul Kumar Verma, Rahul Shukla

et al.

AAPS PharmSciTech, Journal Year: 2024, Volume and Issue: 25(6)

Published: Aug. 2, 2024

Language: Английский

Citations

3